Navigation Links
Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results
Date:2/28/2011

2;Operating income390,024

129,766519,790 Interest expense, net

37,718

(14,719)

(6)

22,999 Other (income) expense, net

(7,354)

7,585

(7)

231Income before income taxes359,660

136,900496,560 Income taxes

93,324

68,948

(8)

162,272Net income$
266,336

$  67,952$   334,288Diluted earnings per share

$
2.27$
2.84Diluted weighted average shares

117,515117,515Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:(1)

To exclude amortization of commercial intangible assets related to marketed products of $62,931 and the impact of an Indevus inventory step-up recorded as part of acquisition accounting of $11,268.(2)

To exclude certain separation payments.(3)

To exclude upfront and milestone payments to partners.(4)

To exclude the impairment of AVEED and PRO2000 for $65,000 and $4,000, respectively.(5)

To exclude Indevus transaction and separation costs of $35,009 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of ($128,090).(6)

To exclude additional interest expense as a result of adopting ASC 470-20 of $15,781 and to exclude the amortization of the premium on debt acquired from Indevus of ($1,062).(7)

To exclude changes in fair value of financial instruments, net.(8)

To reflect the cash tax savings resulting from the Indevus acquisition and the tax effect of the pre-tax adjustments above at applicable tax rates.For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission.

Reconciliation of Projected GAAP Diluted Earnings Per Share to
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
2. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
3. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
4. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
6. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
7. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
9. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
10. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
11. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
(Date:6/18/2013)... June 18, 2013  It has become apparent ... Seating and Mobility, a subsidiary company of The ... repair. This appears to be due to the ... field service employees.  (Logo: ... of these clients are complex mobility users with ...
(Date:6/18/2013)... GARDEN CITY, N.Y. , June 18, 2013 ... announced that it has entered into an exclusive ... and Mid-Atlantic regions with eWellness Corporation ("EWC") for ... "An easy to use physical therapy program ... of diabetes and cardiovascular disease," said Chris ...
Breaking Medicine Technology:Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3
... Aug. 26 Semafore Pharmaceuticals Inc.,announced data presented ... Cancer in Washington, D.C., showing additional antiangiogenic,activity of ... VEGF and Bv8 signaling., PI3K is part ... pathway that,has been shown to play a major ...
... 26 XTENT, Inc.,(Nasdaq: XTNT ) today announced ... trial was published in the most recent issue of ... was,Dr. Pieter R. Stella, M.D., of University Medical Center ... Investigators from 13 clinical,sites across Europe., The one-year ...
Cached Medicine Technology:SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
(Date:6/19/2013)... 2013 Weight gain and obesity have ... concerns including heart disease, kidney failure and high blood ... excess and unnecessary fat, have many people searching for ... hCG diets to not only allow patients to ... also aim to reduce the risk for many weight-related ...
(Date:6/19/2013)... To survive when your plane goes down on a combat mission, ... the most important item in a survival kit is not a ... Kleyne Hour Power of Water radio show, Orr stated that in ... ahead of guns or even food. , According to Orr, the ... carry on planes in Vietnam. He was the only Navy pilot ...
(Date:6/19/2013)... New York,NY (PRWEB) June 19, 2013 ... company officials at SizeItUp formally announced the ... This smartly renovated van is the latest entry in ... for the year 2013. The completely redesigned 2012 Nissan ... the automobile lovers and critics alike. , Provided with ...
(Date:6/19/2013)... McGuff Pharmaceuticals, Inc. continues to ... (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple ... fomerly known as Delalutin™. We are providing this ... approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate ... our pending ANDA, to date, McGuff has responded to ...
(Date:6/19/2013)... 2013 Audibel Hearing Center is ... tinnitus patients, the A2 with Multiflex Tinnitus Technology. ... ringing in the ears. Although bothersome, tinnitus usually ... body. , Using their patent-pending Multiflex Tinnitus Technology, ... comforting sound stimulus that resonates through the patient’s ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2
... boost emotional well-being in hard times , , THURSDAY, May ... women may actually overspend to try to cheer themselves up, ... found that 79 percent said they,d go on a shopping ... listed "depression" and 60 percent listed "feeling a bit low" ...
... to Improve CBO Modeling and Information for PolicymakersWASHINGTON, ... Fight Chronic Disease policy briefing on Capitol Hill, ... James C. Capretta, M.A., released a white paper, ... Diseases: The Current Context and Potential Enhancements." ...
... Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group practice company, announced today that management ... New York City., ... ... ...
... CITY, Calif., May 21 Genomic Health, Inc. (Nasdaq: ... will present results from three studies at the American ... May 29 - June 2, 2009, at the Orange ... markets the widely-adopted Onco type DX(R) breast cancer ...
... 21 Celator Pharmaceuticals today announced that it ... Inc. (Nasdaq: CEPH ). The ... application of Celator,s proprietary technology to an ongoing ... agreement provides an opportunity to leverage the technology ...
... the importance of hearing healthPISCATAWAY, N.J., May 21 ... Hearing Month in Times Square from ... air a 30-second hearing loss awareness video every hour on ... addition, 18 Siemens representatives will be in Times Square and ...
Cached Medicine News:Health News:Shop 'Til You Drop: You May Feel Better 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:IPC The Hospitalist Company, Inc. to Present at Citi's 2009 Healthcare Services Day 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: